TARO'S INFLAMMATORY SKIN OINTMENT APPROVED

Taro Pharmaceutical Industries has received FDA approval for its abbreviated new drug application for Hydrocortisone butyrate ointment, 0.1 percent.

Taro's ointment is bioequivalent to Ferndale Laboratories' Locoid ointment. The ointment is a prescription topical corticosteroid product used in managing inflammatory skin conditions.